Which Six Companies Are in Michael King’s Oncology Wheelhouse?
The Life Sciences Report: Mike, after nearly two decades as a sell-side analyst, you’ve seen any number of new therapeutic trends emerge and new opportunities appear for investors. Back when you and I spoke . . . → Read More: Which Six Companies Are in Michael King’s Oncology Wheelhouse? Similar posts: Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy The Life Sciences Report: Your focus at Vista Partners is... Applying the Venture Capital Model to Public Companies: Hugh Cleland The Life Sciences Report: In your letter to investors dated... Bring Home Profits from Nevada: David Sidders The Gold Report: What is your overall strategy for gold-related...
The Life Sciences Report: Mike, after nearly two decades as a sell-side analyst, you’ve seen any number of new therapeutic trends emerge and new opportunities appear for investors. Back when you and I spoke in 1998–1999, you made a strong case for Immunex Corp. and its antibody fusion protein technology, which would be acquired by Amgen Inc. (AMGN:NASDAQ) for $16 billion ($16B) on the strength of Enbrel (etanercept). That was a great call.
Michael King: Thank you. The antibody revolution is not done … [visit site to read more]
- Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy The Life Sciences Report: Your focus at Vista Partners is...
- Applying the Venture Capital Model to Public Companies: Hugh Cleland The Life Sciences Report: In your letter to investors dated...
- Bring Home Profits from Nevada: David Sidders The Gold Report: What is your overall strategy for gold-related...